Author

William A. Michaud

Massachusetts General HospitalORCID 0000-0002-3664-2094Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Aleigha R. LawlessiD· 2 shared Angelina M. CicerchiaiD· 2 shared Debattama R. SeniD· 2 shared Donald P. LawrenceiD· 2 shared Genevieve Marie BolandiD· 2 shared Hongyan XieiD· 2 shared Jacy FangiD· 2 shared Keith T. FlahertyiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Aleigha R. LawlessORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell BiologyAtherosclerosisPeer-reviewedFeb 10, 2026

Improving Cardiac Resilience to Ischemia/Reperfusion: The Role of Butyrate in Mitochondrial and Metabolic Recovery

Bhuban Ruidas, William A. Michaud, Sar R. Lindner…·Seyed Alireza Rabi

This paper investigates the therapeutic potential of butyrate to restore metabolic function in cardiomyocytes after ischemia/reperfusion injury, showing improved mitochondrial function and reduced apoptosis.

6 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 19, 2025

Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ tumor-infiltrating lymphocytes

Hongyan Xie, Aiping Jiang, Aonkon Dey…·Russell William Jenkins

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

DOI 10.1101/2025.11.19.689204

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologyCell Reports MedicinePeer-reviewedJun 27, 2025

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

Or‐Yam Revach, Angelina M. Cicerchia, Ofir Shorer…·Russell William Jenkins

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

19 citationstop 2%

mousebulk RNA-seq

𝕏 PostBluesky